Article

Warburg Pincus completes acquisition of Bausch & Lomb

New York-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.

New York

-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.  

“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for [B&L] and advance our leadership in the eye health industry,” said Ronald L. Zarrella, chairman and chief executive officer of B&L, Rochester, NY.
 
Elizabeth H. Weatherman, a Warburg Pincus managing director, said, “We look forward to helping the company build upon its rich heritage and premier brand in ophthalmology.”

B&L stock has been delisted on the New York Stock Exchange. Under the terms of the acquisition agreement, B&L shareholders are entitled to receive $65 in cash for each share of B&L common stock that they hold.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.